We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CMPX market cap is 265.5M. The company's latest EPS is USD -0.3571 and P/E is -5.40.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 850k | 0 | 0 |
| Operating Income | -15.39M | -12.77M | -15.04M | -12.24M | -16.57M |
| Net Income | -13.42M | -10.79M | -13.08M | -10.48M | -15.03M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 850k |
| Operating Income | -27.81M | -81.88M | -41.66M | -50.36M | -56.63M |
| Net Income | -29.5M | -82.18M | -39.23M | -42.49M | -49.38M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 156.88M | 161.14M | 155.61M | 149.15M | 140.4M |
| Total Liabilities | 8.34M | 4.08M | 9.51M | 10.75M | 15.17M |
| Total Equity | 148.54M | 157.06M | 146.1M | 138.4M | 125.23M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 51.91M | 153.76M | 199.65M | 156.88M | 140.4M |
| Total Liabilities | 11.97M | 13.68M | 18.01M | 8.34M | 15.17M |
| Total Equity | 39.95M | 140.08M | 181.64M | 148.54M | 125.23M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -40.62M | -13.89M | -24.64M | -35.69M | -44.86M |
| Investing | 26.97M | -4.1M | 2.38M | 31.4M | 46.77M |
| Financing | 2.94M | 17.43M | 17.43M | 17.43M | 17.34M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -26.8M | -19.67M | -34.13M | -40.62M | -44.86M |
| Investing | 38k | -1.77M | -151.2M | 26.97M | 46.77M |
| Financing | 48.54M | 118.61M | 75.76M | 2.94M | 17.34M |
| Market Cap | 265.5M |
| Price to Earnings Ratio | -5.40 |
| Price to Sales Ratio | 316.39 |
| Price to Cash Ratio | 6.14 |
| Price to Book Ratio | 2.13 |
| Dividend Yield | - |
| Shares Outstanding | 138.28M |
| Average Volume (1 week) | 806.8k |
| Average Volume (1 Month) | 2.81M |
| 52 Week Change | 35.21% |
| 52 Week High | 4.08 |
| 52 Week Low | 0.765 |
| Spread (Intraday) | 0.35 (15.56%) |
| Company Name | Compass Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.compasstherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
